Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684929 | 0.83 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL38651021 | 0.82 | L3MBTL1 (0.44) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL27368089 | 0.82 | L3MBTL1 (0.44) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL3684101 | 0.81 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL14248446 | 0.80 | SLC5A2 (0.44) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL500101 | 0.80 | HTR2A (0.33) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL499606 | 0.80 | SLC5A2 (0.56) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL500201 | 0.79 | CCR5 (0.40) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL499821 | 0.78 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL16608734 | 0.78 | PKM (0.46) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | SLC5A2 2/4885SLC5A1 1/4885HTR2A 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.